<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113240</url>
  </required_header>
  <id_info>
    <org_study_id>311/4114</org_study_id>
    <nct_id>NCT03113240</nct_id>
  </id_info>
  <brief_title>Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients</brief_title>
  <official_title>Effects of Enteral Glutamine on Intestinal Permeability in Hospitalized Patients With Enteral Feeding in Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glutamine-induced recovery in intestinal barrier function by reducing bacterial translocation
      was demonstrated in previous studies. In this trial, intensive care unit patients with
      enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 10 days
      and the effects of the intervention on intestinal permeability will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blind, controlled trial will be conducted in general intensive care unit
      (ICU) in Tehran, Iran. After a full review of the inclusion and exclusion criteria and
      explanation of the risks and benefits of the study, written consent form will be completed.
      The participants are 60 eligible hospitalized patients with enteral feeding in ICU, aged â‰¥ 18
      years. Intervention patients will be received 0.3 g/kg/day of glutamine along with enteral
      formula for 10days and control patients will be received maltodextrin along with enteral
      formula for 10 days. Patients will be evaluated for plasma endotoxin and plasma zonulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">October 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma endotoxin concentration</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>The levels of plasma endotoxin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma zonulin concentration</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>The levels of plasma zonulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma antiendotoxin IgG and Ig M concentration</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>The levels of plasma antiendotoxin IgG and Ig M concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal complication</measure>
    <time_frame>Day10</time_frame>
    <description>abdominal distention, vomiting, diarrhea and constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in ICU</measure>
    <time_frame>Day 10</time_frame>
    <description>Mortality rate in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU</measure>
    <time_frame>Day 10</time_frame>
    <description>Duration of stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe sepsis</measure>
    <time_frame>Day 10</time_frame>
    <description>according to the American College of Chest Physicians and the Society of Critical Care Medicine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum Glutamin</measure>
    <time_frame>baseline, Day 5, Day 10</time_frame>
    <description>The levels of serum Glutamin</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Critical Illness</condition>
  <condition>Enteral Nutrition</condition>
  <condition>Intestinal Permeability</condition>
  <arm_group>
    <arm_group_label>Glutamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamin</intervention_name>
    <description>Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.</description>
    <arm_group_label>Glutamin</arm_group_label>
    <other_name>L-glutamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin mixed with water given via NG tube q 4 hours.</description>
    <arm_group_label>maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (&gt;18 years old) admitted to ICU

          -  Start of study intervention within 48 hours after ICU admission

          -  Expected to require enteral nutrition for at least 72 hours aiming for full enteral
             nutrition and receive at least 80 percent of enteral formula during the first 48 hour

          -  Written informed consent of patient or written informed consent of legal
             representative

        Exclusion Criteria:

          -  Enrollment in a related ICU interventional study

          -  Requiring other specific enteral nutrition for medical reason

          -  Death or Discharge before 5th day

          -  Having any contra-indication to receive enteral nutrition

          -  Pregnant patients or lactating with the intent to breastfeed

          -  BMI &lt;18 or &gt; 40.0 kg/m2

          -  Have life expectancy of &lt;6 mo

          -  Patients who are moribond

          -  Liver cirrhosis- Child's class C liver disease

          -  Have seizure disorder requiring anticonvulsant

          -  History of allergy or intolerance to the study product components

          -  Receiving glutamine during two weeks before start study product

          -  Have other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahra Vahdat Shariatpanahi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Shohada Tajrish Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Rao R, Samak G. Role of Glutamine in Protection of Intestinal Epithelial Tight Junctions. J Epithel Biol Pharmacol. 2012 Jan;5(Suppl 1-M7):47-54.</citation>
    <PMID>25810794</PMID>
  </reference>
  <reference>
    <citation>dos Santos Rd, Viana ML, Generoso SV, Arantes RE, Davisson Correia MI, Cardoso VN. Glutamine supplementation decreases intestinal permeability and preserves gut mucosa integrity in an experimental mouse model. JPEN J Parenter Enteral Nutr. 2010 Jul-Aug;34(4):408-13. doi: 10.1177/0148607110362530.</citation>
    <PMID>20631386</PMID>
  </reference>
  <reference>
    <citation>McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, McCarthy MS, Davanos E, Rice TW, Cresci GA, Gervasio JM, Sacks GS, Roberts PR, Compher C; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016 Feb;40(2):159-211. doi: 10.1177/0148607115621863. Erratum in: JPEN J Parenter Enteral Nutr. 2016 Nov;40(8):1200.</citation>
    <PMID>26773077</PMID>
  </reference>
  <reference>
    <citation>Kreymann KG, Berger MM, Deutz NE, Hiesmayr M, Jolliet P, Kazandjiev G, Nitenberg G, van den Berghe G, Wernerman J; DGEM (German Society for Nutritional Medicine), Ebner C, Hartl W, Heymann C, Spies C; ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Intensive care. Clin Nutr. 2006 Apr;25(2):210-23. Epub 2006 May 11.</citation>
    <PMID>16697087</PMID>
  </reference>
  <reference>
    <citation>D'Souza R, Powell-Tuck J. Glutamine supplements in the critically ill. J R Soc Med. 2004 Sep;97(9):425-7. Review.</citation>
    <PMID>15340021</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 8, 2018</last_update_submitted>
  <last_update_submitted_qc>April 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University</investigator_affiliation>
    <investigator_full_name>Zahra Vahdat Shariatpanahi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Glutamin</keyword>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Intestinal Permeability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

